Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Express Scripts
Harvard Business School
Johnson and Johnson
Colorcon

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for RDEA3170

See Plans and Pricing

« Back to Dashboard

Drug Development Status for RDEA3170: Patents, clinical trial progress, indications

RDEA3170 is an investigational drug.

There have been 15 clinical trials for RDEA3170. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2014.

The most common disease conditions in clinical trials are Gout, Hyperuricemia, and Renal Insufficiency. The leading clinical trial sponsors are Ardea Biosciences, Inc., AstraZeneca, and PAREXEL Early Phase Clinical Unit-Los Angeles.

There are seven US patents protecting this investigational drug and one hundred and fifteen international patents.

Recent Clinical Trials for RDEA3170
TitleSponsorPhase
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UAAnalytical Laboratory (Pharmacokinetic Sample Analysis): USAPhase 2
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UAClinical Laboratory: USAPhase 2
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UAContract Research Organization: USAPhase 2

See all RDEA3170 clinical trials

Clinical Trial Summary for RDEA3170

Top disease conditions for RDEA3170
Top clinical trial sponsors for RDEA3170

See all RDEA3170 clinical trials

US Patents for RDEA3170

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
RDEA3170   Start Trial Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (Shanghai, CN)   Start Trial
RDEA3170   Start Trial URAT1 inhibitor Nippon Chemiphar Co., Ltd. (Tokyo, JP) J-Pharma Co., Ltd. (Kanagawa, JP) DeThree Res. Lab. Inc. (Ibaraki, JP)   Start Trial
RDEA3170   Start Trial Thioacetate compounds, compositions and methods of use Ardea Biosciences, Inc. (San Diego, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Harvard Business School
Moodys
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.